Intercellular adhesion molecule 1 and tumor necrosis factor alpha in asthma and persistent allergic rhinitis: relationship with disease severity

• Published in: Annals of allergy, asthma, & immunology Vol. 97; no. 1; p. 66
• Main Authors: Gorska-Ciebiada, Malgorzata, Ciebiada, Maciej, Gorska, Magdalena M, Gorski, Pawel, Grzelewska-Rzymowska, Iwona
• Format: Journal Article
• Language: English
• Published: United States 01.07.2006
• Subjects: Adolescent; Adult; Aged; Asthma - blood; Asthma - epidemiology; Asthma - pathology; Biomarkers; Blood Vessels - chemistry; Bronchial Hyperreactivity - blood; Bronchial Hyperreactivity - epidemiology; Bronchial Provocation Tests; Comorbidity; Female; Humans; Intercellular Adhesion Molecule-1 - analysis; Intercellular Adhesion Molecule-1 - blood; Male; Methacholine Chloride; Middle Aged; Nasal Mucosa - blood supply; Nasal Mucosa - chemistry; Nasal Mucosa - pathology; Prevalence; Rhinitis, Allergic, Perennial - blood; Rhinitis, Allergic, Perennial - epidemiology; Rhinitis, Allergic, Perennial - pathology; Severity of Illness Index; Tumor Necrosis Factor-alpha - analysis
• ISSN: 1081-1206
• DOI: 10.1016/S1081-1206(10)61372-5

Tumor necrosis factor alpha (TNF-alpha) is involved in the up-regulation of intercellular adhesion molecule 1 (ICAM-1). Allergic rhinitis is often associated with bronchial hyperresponsiveness. We investigated the relationship between allergic airway disease severity and serum concentrations of soluble ICAM-1 (sICAM-1) and TNF-alpha and nasal expression of ICAM-1. Serum concentrations of TNF-alpha and sICAM-1 were investigated in 85 adults with persistent rhinitis and 90 patients with asthma. Seventy patients with rhinitis were challenged with methacholine. Nasal biopsy for ICAM-1 expression was performed in 6 patients with moderate-severe rhinitis and in 6 patients with mild rhinitis. In patients with rhinitis, serum sICAM-1 concentrations were as follows: group without bronchial hyperresponsiveness (n = 29), 206.85 ng/mL; group with bronchial hyperresponsiveness but without asthma symptoms (n = 20), 233.39 ng/mL; and group with newly recognized asthma (n = 21), 260.06 ng/mL. The sICAM-1 level was significantly lower in patients with mild rhinitis (216.21 ng/mL) than in patients with moderate-severe rhinitis (244.08 ng/mL). Nasal ICAM-1 expression was significantly higher in the moderate-severe rhinitis group than in the mild rhinitis group. In patients with asthma, serum concentrations of sICAM-1 were as follows: patients with mild asthma, 272.8 ng/mL; patients with moderate asthma, 340.16 ng/mL; patients with severe asthma without oral corticosteroids therapy, 426.74 ng/mL; and patients with severe asthma with oral corticosteroids therapy, 314 ng/mL. The serum TNF-alphaa concentration differed between patients with rhinitis (n = 15) (1.065 pg/mL) and patients with asthma (n = 12) (3.46 pg/mL). Among patients with asthma, TNF-alpha concentrations were similar in all groups classified according to the disease severity. sICAM and ICAM-1 expression correlates with airways diseases severity.